Successful Pharmacy Compounding Relies on Keeping the Focus on Patients | ASHP Midyear 2025

In order for businesses to ensure safe and effective compliant pharmacy compounding, there is a need for addressing gaps and ensuring strong oversight, trained personnel, appropriate facilities, and careful use of emerging artificial intelligent (AI) tools. Ultimately, pharmacy compounding and its compliance aspects should focus on safely and effectively improving patient outcomes.

“These are some of the more consistent gaps that we continue to see, and each of these put compounded preparations at risk. Altogether, if all of those things are kind of slipping through the cracks, then they put patients at risk as well,” Annie Lambert, PharmD, BCSCP, clinical program manager of compliance solutions at Wolters Kluwer, told Drug Topics. “We need to keep the patients at the focus of our compliance.”

During the 2025 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition, Lambert met with Drug Topics to discuss emerging trends in the pharmacy compounding space and how the unique nature of compounding relies on a myriad of systems and manpower to ensure the utmost patient safety outcomes.

In this interview, she discussed the roles of the FDA and other regulatory bodies in overseeing compounding businesses. Lambert also explored how events in the past—such as glucagon-like peptide-1 (GLP-1) shortages from 2024—inform future decisions and how the industry is making way for emerging technologies, like AI, that further drive compounding safety, efficiency, and effectiveness.

Learn more from Lambert’s expert industry insights and find out how the compounding industry is serving patients across the country in a regulated and cost-effective manner.

READ MORE: ASHP Midyear Clinical Meeting and Exhibition

Don’t get left behind: Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.